GAYATRI BIOORGANICS LTD.

Gayatri BioOrganics Limited has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the Quarter and Half year ended September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. A board meeting is scheduled to approve these financial results, with a separate intimation to be sent to the stock exchange regarding the meeting notice. Designated persons and their immediate relatives are prohibited from trading during this period.

Gayatri BioOrganics Limited has announced its 35th Annual General Meeting (AGM) will be held on September 23, 2026, at 11:00 a.m. via Video Conferencing/Other Audio-Visual Means. The meeting will cover ordinary business, including the adoption of audited financial statements for FY 2025-26 and the re-appointment of a director retiring by rotation. A key special business item is the proposed change of the company's name from "Gayatri BioOrganics Limited" to "Ananth Bioorganics Limited". The cut-off date for determining voting rights is September 16, 2026.

Gayatri BioOrganics Limited has announced its 35th Annual General Meeting (AGM) scheduled for September 23, 2026, to be held via Video Conferencing. The company has submitted its Annual Report for the Financial Year 2025-26, which includes the audited financial statements and reports. Key agenda items include the adoption of financial statements and the re-appointment of a director retiring by rotation. A significant special business item is the proposed change of the company's name from "Gayatri BioOrganics Limited" to "Ananth Bioorganics Limited". The cut-off date for determining voting rights is September 16, 2026.

The Chairman and Non-Executive Director of Gayatri BioOrganics Ltd has tendered his resignation from his positions, including board committees. The resignation is effective from August 5, 2026, citing professional responsibilities and personal reasons. The company is requested to acknowledge the receipt and submit necessary forms to the Registrar of Companies (ROC) and Stock Exchanges.

Gayatri BioOrganics Limited announced key decisions from its Board meeting on August 4, 2026. Mr. Venkata Sandeep Kumar Reddy Tikkavarapu resigned as Chairman and Non-Executive Director, effective August 5, 2026, due to professional and personal reasons. Concurrently, Mr. Sreedhara Reddy Kanaparthi was re-designated from Whole-time Director to Chairman and Managing Director for a three-year term, effective August 5, 2026, subject to member approval. The Board also approved the unaudited financial results for the quarter ended June 30, 2026, and proposed a change in the company's name to 'Ananth BioOrganics Limited' or similar, pending regulatory and member approvals. The 35th Annual General Meeting is scheduled for September 23, 2026.

Gayatri BioOrganics Limited held a board meeting on August 4, 2026, where they considered and approved the un-audited financial results for the quarter ended June 30, 2026. The company also approved a change in its name to Ananth BioOrganics Limited or similar variations, subject to regulatory and member approvals. Key management changes were noted, including the resignation of Mr. Venkata Sandeep Kumar Reddy Tikkavarapu as Chairman and Non-Executive Director and the change in designation of Mr. Sreedhara Reddy Kanaparthi from Whole-time Director to Chairman and Managing Director. The board also approved the Directors' Report for FY 2025-26 and scheduled the 35th Annual General Meeting for September 23, 2026. Additionally, a new Memorandum and Articles of Association were approved.

Gayatri BioOrganics Limited announced its unaudited financial results for the quarter ended June 30, 2026. The board also approved a significant change in the company's name to Ananth BioOrganics Limited or a similar variant, subject to regulatory and member approvals. Additionally, the board noted the resignation of Mr. Venkata Sandeep Kumar Reddy Tikkavarapu as Chairman and Non-Executive Director and approved the change in designation of Mr. Sreedhara Reddy Kanaparthi from Whole-time Director to Chairman and Managing Director for a three-year term. The 35th Annual General Meeting is scheduled for September 23, 2026, and the company will adopt a new Memorandum and Articles of Association.

Gayatri BioOrganics Limited has announced that its Board of Directors will convene on August 4, 2026, to consider and approve the Un-audited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. Additionally, the board will discuss any other business with the permission of the Chair. The company has also informed that the trading window for its securities is currently closed from July 1, 2026, and will remain shut until 48 hours after the declaration of the financial results, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Gayatri BioOrganics Limited has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026. This measure is to prevent insider trading during the period leading up to and immediately following the announcement of financial results. A board meeting will be convened to approve these results.

Gayatri BioOrganics Ltd has submitted revised audited financial results for the quarter and year ended March 31, 2026, due to typographical errors in the previously submitted results. The revision, following a Board Meeting on May 19, 2026, has no impact on the company's financial performance, profitability, or cash flows. The company has requested the exchange to replace the earlier filed version with the revised results.